Diabetes

Ozempic approved for type 2 diabetes

(HealthDay)—Ozempic (semaglutide) has been approved by the U.S. Food and Drug Administration as a weekly injection to treat type 2 diabetes in adults.

Cardiology

Highest adverse effect rates for three drugs in parkinson's

(HealthDay)—Ropinirole, bromocriptine, and piribedil are associated with the highest incidence rates of adverse effects in Parkinson's disease, according to a review published online Sept. 4 in CNS Neuroscience & Therapeutics.

Pediatrics

Asthma drug tied to nightmares, depression

(HealthDay)—The asthma medication Singulair (montelukast) appears linked to neuropsychiatric side effects, such as depression, aggression, nightmares and headaches, according to a new review by Dutch researchers.

Oncology & Cancer

FDA approves aliqopa for follicular lymphoma

(HealthDay)—Aliqopa (copanlisib) has been approved by the U.S. Food and Drug Administration to treat adults with relapsed follicular lymphoma who have received at least two prior treatments with certain other drugs.

Medications

Finding better ways to reduce serious drug side effects

Many of the medicines we depend on to treat disease—and even to save our lives—pose potentially serious risks along with their benefits. Data from the U.S. Centers for Disease Control and Prevention indicate that about ...

Cardiology

Benefits of continued statin use after adverse reactions

Statins are known to reduce the risk of death and cardiovascular events for people who are at high risk; however, as many as 75 percent of patients discontinue statin therapy within two years, often after reporting an adverse ...

Psychology & Psychiatry

Pharmacophobia—what is it and how can be overcome

There is little current interest in research into patients' attitudes toward medications. In the 1960s, psychiatric researchers including Uhlenhuth, Rickels and Covi focused on this area, but this research topic needs to ...

Diseases, Conditions, Syndromes

Case report describes adverse reaction to clindamycin

(HealthDay)—In a case report published online April 17 in the Journal of Clinical Pharmacy and Therapeutics, acute generalized exanthematous pustulosis secondary to clindamycin therapy is described.

page 9 from 17